Skip to content

Xeris Biopharma Holdings, Inc. XERS Other Non-Current Liabilities

Other Non-Current Liabilities at other companies

Eli Lilly logo
Eli LillyLLY
$4.09B+78.5%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$3.54M-14.8%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$42M+145%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$1.86M-61.9%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$16.45M+134%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$4.93M+179%

Other financials

Income statement

See full
Revenue$83.1M+38.3%
Gross profit$72.6M+41.2%
Operating income$7.9M+356%
Net income$2.2M+124%
EPS (diluted)$0.01+117%

Balance sheet

See full
Cash & equivalents$111.8M+91.2%
Total debt$258.6M-3.8%
Total equity$13.0M+137%
Total assets$392.0M+24.3%

Cash flow

See full
Operating cash flow$9.9M+198%
CapEx$131.0K
Free cash flow-$29.1M

Valuation

See full
Market cap$1.28B+76.9%
Enterprise value$1.42B+52.7%
P/E106.4×
P/S4.1×+0.8×

Profitability

See full
Gross margin85.9%+3.7pp
Operating margin11.4%+7.7pp
Net margin3.8%+2.1pp

Returns & leverage

See full
Return on equity-209.8%
Debt / equity19.9×
Current ratio2.1×+0.4×

Where this comes from

Reported directly by Xeris Biopharma Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.

The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xeris Biopharma Holdings, Inc.'s other non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xeris Biopharma Holdings, Inc.'s other non-current liabilities?
Xeris Biopharma Holdings, Inc. (XERS) reported other non-current liabilities of $8.13M in Q1 2026.
How has Xeris Biopharma Holdings, Inc.'s other non-current liabilities changed year-over-year?
Xeris Biopharma Holdings, Inc.'s other non-current liabilities increased by 68.1% year-over-year, from $4.83M to $8.13M.
What is the long-term trend for Xeris Biopharma Holdings, Inc.'s other non-current liabilities?
Over 5 years (2020 to 2025), Xeris Biopharma Holdings, Inc.'s other non-current liabilities has grown at a 18.9% compound annual growth rate (CAGR), from $3.53M to $8.4M.
What does other non-current liabilities mean?
Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.